Safety and effectiveness of Omnitrope® (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data

Philippe Backeljauw, Shankar Kanumakala, Sandro Loche, Karl Otfried Schwab, Bradley S. Miller, Richard Levy, Kenneth McCormick, Hichem Zouater, Markus Zabransky, Kim Campbell

Research output: Contribution to journalArticlepeer-review

Abstract

There are known geographical differences in growth hormone deficiency (GHD) patient populations and treatment practices. Here, we present a comparison of safety and effectiveness data from patients treated with recombinant human growth hormone (rhGH) in the USA versus other countries. PAtients TReated with Omnitrope® (PATRO) Children is an international, non-interventional study with Omnitrope® (somatropin, Sandoz Inc.). All visits and assessments are carried out according to routine clinical practice, and doses of Omnitrope® are given according to country-specific prescribing information. By September 2018, 294 patients had been enrolled in the USA (53% rhGH-naïve) and 6206 patients had been enrolled across 13 other countries (international group; 86% rhGH-naïve). The most common indication in both groups was GHD. Overall, 194 US patients (66%) and 2977 international patients (48%) experienced adverse events (AEs; 886 and 11,716 events, respectively), most of which were of mild or moderate intensity. The AEs were suspected to be treatment-related in five US patients (1.7%) and 452 international patients (7.3%). All reported neoplasms were benign, non-serious, and considered unrelated to rhGH therapy. No cases of diabetes mellitus or hyperglycemia were reported. In rhGH-naïve GHD patients, after 3 years of rhGH therapy, the improvement in mean height SD score from baseline was + 1.25 and + 1.35 in US and international patients, respectively. Conclusion: Omnitrope® treatment appears to be well tolerated and effective in US patients and those from other countries. Across the pediatric indications included, there was no evidence of an increased risk of developing uncommon or unexpected AEs with rhGH. Trial registration: NA.What is Known:• Continued monitoring of patients treated with recombinant human growth hormone (rhGH) is important, particularly in terms of diabetogenic potential and the risk of malignancies.• The PAtients TReated with Omnitrope® (PATRO) Children study is a long-term, post-marketing surveillance program for the rhGH Omnitrope®.What is New:• Omnitrope® is well tolerated and effective in US patients, and those from other countries.• Across all indications included, there were no unexpected adverse events and there was no evidence of an increased risk of developing malignancies or diabetes.

Original languageEnglish (US)
JournalEuropean Journal of Pediatrics
Volume181
Issue number6
DOIs
StateAccepted/In press - 2022

Bibliographical note

Funding Information:
Medical writing support was provided by Tony Reardon of Aura, a division of Spirit Medical Communications Group Ltd, and was supported by Sandoz/Hexal AG. Statistical input was provided by Masiur Rahman of Novartis Pharmaceuticals, Wallingford, CT, USA. The authors would like to thank the investigators and patients who participated in the PATRO Children study.

Publisher Copyright:
© 2022, The Author(s).

Keywords

  • Growth hormone
  • Non-interventional study
  • Omnitrope®
  • PATRO Children
  • Pediatrics
  • Human Growth Hormone/adverse effects
  • Humans
  • Neoplasms/drug therapy
  • Diabetes Mellitus
  • Dwarfism, Pituitary/chemically induced
  • Product Surveillance, Postmarketing
  • Recombinant Proteins/adverse effects
  • Growth Disorders/drug therapy
  • Child
  • Longitudinal Studies

PubMed: MeSH publication types

  • Multicenter Study
  • Journal Article

Fingerprint

Dive into the research topics of 'Safety and effectiveness of Omnitrope® (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data'. Together they form a unique fingerprint.

Cite this